Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Fat Loss and Metabolism

CAGRILINTIDE

A long-acting version of amylin, the fullness hormone your pancreas releases alongside insulin. Slows stomach emptying and curbs appetite. Often paired with semaglutide (the “CagriSema” combo) for additive weight loss.

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

A long-acting version of amylin, the fullness hormone your pancreas releases alongside insulin.

Slows stomach emptying and curbs appetite.

Often paired with semaglutide (the “CagriSema” combo) for additive weight loss.

What It Does

Cagrilintide is a long-acting amylin analog.

It signals satiety, slows gastric emptying, and reduces food intake through a mechanism complementary to GLP-1 drugs; which is why amylin + GLP- 1 stacks outperform either alone.

Once-weekly dosing.

Reconstitution

Vial SizeBAC Water / SolventConcentration
2 mg+ 0.4 mL5 mg/mL
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

PhaseFrequencyAmountNotes
Weeks 1–4Once weekly0.25 mgTitrate slowly, nausea is dose-dependent.
Weeks 5–8Once weekly0.5 mg
Weeks 9–12Once weekly1.0 mg
Weeks 13–16Once weekly1.7 mg
Week 17+Once weekly2.4 mgResearch-target maintenance. Do not exceed ~4.5 mg/week.
Cycle & Timing

titrate over 16–20 weeks to the 2.4 mg maintenance dose; escalate only when the current dose is well tolerated.

Timing

same day each week, any time, with or without food. Rotate injection sites. Stack: commonly combined with semaglutide (CagriSema), titrate the two together and expect stronger GI effects.

Population Considerations

Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises testosterone, SHBG and gonadotropins as weight drops, improves sperm and erectile function, and preserves fertility (unlike T Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises testosterone, SHBG and gonadotropins as weight drops, improves sperm and erectile function, and preserves fertility (unlike TRT).

Handling & Stacking

Injection site
SubQ, abdomen/thigh. Rotate.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F.
  • Best used within ~2–4 weeks, kept cold (structure-based estimate, no published data); that is close to the 28- day sterility limit, so use whichever comes first.
Side effects
Nausea, reduced appetite, constipation/diarrhea, injection-site reactions. GI effects are dose-dependent and ease with slow titration.
What to expect
  • Earlier satiety and smaller portions within weeks; steady weight loss over months (strongest with a GLP-1).
  • Supply math 2mg → 7 vials | 5mg → 3 vials | 10mg → 2 vials (16-wk titration to 2.4 mg/wk)
Pairs well with
Semaglutide / Tirzepatide / Retatrutide (amylin + incretin synergy); Lipo-C / L-Carnitine (metabolic support)
Avoid
Active gastroparesis. Pregnancy
Approved drug
Pramlintide (Symlin) is the approved amylin drug, but for diabetes, not weight loss. For weight loss: semaglutide or tirzepatide.

Safety & Patient Education

Contraindications
Pregnancy and lactation Active or severe gastroparesis Hypersensitivity to amylin analogs Type 1 diabetes / on insulin without supervision (hypoglycemia risk)
Warnings
Hypoglycemia risk when combined with insulin or sulfonylureas Marked GI effects (nausea, vomiting); titrate slowly Dehydration from GI losses, can stress the kidneys Research compound, no long-term human safety data outside trials
Drug interactions
Insulin / sulfonylureas: additive hypoglycemia, reduce those doses, monitor glucose Oral drugs with narrow timing (e.g. some antibiotics, levothyroxine): delayed emptying alters absorption Other GLP-1 / amylin agents: additive GI and appetite effects
Labs
  • Fasting glucose / HbA1c (baseline + periodic), especially if diabetic Renal function if significant vomiting/diarrhea Weight, blood pressure, heart rate trend Out of range?
  • Rising glucose/HbA1c = creeping toward diabetes (recheck, tighten diet); falling eGFR = kidney strain, usually dehydration (hydrate, hold).
Stop criteria
Severe or persistent vomiting / inability to stay hydrated Severe abdominal pain Signs of hypoglycemia when stacked with insulin/sulfonylureas Pregnancy
Patient education
Go slow on titration, rushing the dose causes most of the nausea Stop and seek care for severe abdominal pain or persistent vomiting
References
researchdosing · peptidedosages · PubMed · thepeptidereport · GLP-1 sex differences · Jensterle 2020